Novel chP3R99 mAb reduces subendothelial retention of atherogenic lipoproteins in Insulin-Resistant rats:Acute treatment versus long-term protection as an idiotypic vaccine for atherosclerosis

Author:

Soto YosdelORCID,Hernández Arletty,Sarduy Roger,Brito Victor,Marleau Sylvie,Vine Donna F.ORCID,Vázquez Ana M.,Proctor Spencer D.ORCID

Abstract

ABSTRACTBackgroundAtherosclerosis is triggered by the retention of apolipoprotein B-containing lipoproteins by proteoglycans. In addition to LDL, remnant lipoproteins have emerged as pivotal contributors to this pathology, particularly in the context of insulin resistance and diabetes. We have recently reported anti-atherogenic properties of a novel monoclonal antibody (chP3R99) that recognizes sulfated glycosaminoglycans on arterial proteoglycans.Methods and ResultsSolid-phase assays demonstrated that chP3R99 effectively blocked over 50% lipoprotein binding to chondroitin sulfate and vascular extracellular matrixin vitro. The pre-perfusion of chP3R99 (passive/competitive effect) resulted in specific antibody-arterial accumulation and reduced fluorescent lipoprotein retention by ∼60% in insulin resistant JCR:LA-cprats. This (passive) reduction was dose-dependent (25 µg/mL–250 µg/mL), effectively decreasing deposition of cholesterol associated with lipoproteins. In a five-week vaccination study in insulin resistant rats with (200 µg SC, once a week), chP3R99 reduced arterial lipoprotein retention, and was associated with the production of anti-CS antibodies (Ab3) able to accumulate in the arteries (dot-blot). Neither the intravenous inoculation of chP3R99 (4.5 mg/kg), nor the immunization with this antibody displayed adverse effects on lipid or glucose metabolism, insulin resistance, liver function, blood cell indices, or inflammation pathways in JCR:LA-cprats.ConclusionBoth acute (passive) and long-term administration of chP3R99 antibody reduced LDL and remnant lipoprotein interaction with proteoglycans in an insulin-resistant setting. These findings support the innovative approach of targeting pro-atherogenic lipoprotein retention by this mAb as a passive therapy or as an idiotypic vaccine for atherosclerosis.GRAPHICAL ABSTRACT

Publisher

Cold Spring Harbor Laboratory

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3